Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C |
| |
| Affiliation: | 1. Department of Medicine, New York Medical College, Metropolitan Hospital Center, 1901 First Avenue, New York 10029, NY, USA;2. Division of Gastroenterology, New York Medical College, Metropolitan Hospital Center, 1901 First Avenue, New York 10029, NY, USA;3. Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, Memphis, TN 38014, USA;1. Department of Gastroenterology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain;2. Facultad de Medicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain;3. Department of Gastroenterology, Hospital Universitario Puerta de Hierro, Madrid, Spain;4. Neurogastroenterology Motility Unit, Department of Gastroenterology, Hospital Clínic, University of Barcelona, Barcelona, Spain;1. Professor at Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Cairo, Egypt;2. Professor of Medical Oncology, Faculty of Medicine, Beni Suef University, Cairo, Egypt;3. Assistant Lecturer at Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Cairo, Egypt;1. Laboratorio de Microbiología, Hospital General La Mancha Centro, Ciudad Real, España;2. Servicio de Medicina Interna, Hospital General La Mancha Centro, Ciudad Real, España;3. Unidad de Apoyo a la Investigación, Hospital General La Mancha Centro, Ciudad Real, España |
| |
| Abstract: | Hepatitis C virus (HCV) has long been associated with several extrahepatic manifestations, including increased cardiovascular risk. The emergence of direct-acting antivirals (DAAs) has allowed us to evaluate the potential reversal of these manifestations after successful treatment. Therefore, many studies have provided significant takeaways regarding the positive effect of DAAs therapy on insulin resistance, type 2 diabetes mellitus, cardiovascular disease and atherosclerosis. In contrast, studies have shown detrimental effects on lipid metabolism and indeterminate results regarding renal function and uric acid metabolism. Nevertheless, as more and more patients achieve sustained virological response, the effects of HCV eradication on cardiometabolic processes will be extensively studied, allowing more reliable conclusions on the extent of extrahepatic outcomes. |
| |
| Keywords: | Direct-acting antivirals Hepatitis C Cardiovascular risk Dyslipidemia Insulin resistance Renal function Antivirales de acción directa Hepatitis C Riesgo cardiovascular Dislipidemia Resistencia a la insulina Función renal |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
